CERVOMED INC (CRVO)
(Delayed Data from NSDQ)
$7.79 USD
-0.31 (-3.83%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $7.80 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRVO 7.79 -0.31(-3.83%)
Will CRVO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRVO
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates
CRVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains?
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
Other News for CRVO
Is CRVO poised for a decline? 180 Bearish Setup shows up after sinking 3.83%
Is CRVO set to breakout? NR7 shows up after climbing 3.98%
CRVO forms Lower Bollinger Band Walk on September 17
New Downtrend appears for CRVO after 5.04% move
CervoMed (CRVO) Advances Dementia Treatment with Neflamapimod